Multisystem Inflammatory Syndrome in an Adult After COVID-19 Vaccination

Main Article Content

Kevin Chien
Lisa Duffett
Dimitrios Scarvelis

Keywords

Vaccine, COVID-19

Abstract

Multisystem inflammatory syndrome in adults (MIS-A) is a hyperinflammatory syndrome associated with COVID-19, for which our understanding of diagnosis and treatment continues to evolve. We present a case of a 62-year-old woman with fever, fatigue, and general malaise with pancytopenia and significantly elevated inflammatory markers 3½ weeks after the first dose of her Pfizer-BioNTech COVID-19 vaccine consistent with MIS-A post-vaccination. Most cases of MIS-A have been associated with previous COVID-19 infection, but our case highlights that MIS-A is a potentially rare adverse event post-vaccination, even in individuals without previous COVID-19 infection.


Résumé
Le syndrome inflammatoire multisystémique chez les adultes (SIM-A) est un syndrome hyperinflammatoire associé à la COVID-19 pour lequel notre compréhension du diagnostic et du traitement ne cesse d’évoluer. Nous rapportons le cas d’une femme de 62 ans éprouvant de la fièvre, de la fatigue et un malaise général qui a présenté une pancytopénie et une élévation considérable des marqueurs inflammatoires trois semaines et demie après avoir reçu sa première dose du vaccin contre la COVID-19 de Pfizer-BioNTech, ce qui corre-spond à un SIM-A post-vaccination. La plupart des cas de SIM-A sont associés à une infection antérieure à la COVID-19, mais ce cas précis met en évidence que le SIM-A est un événement indésirable potentiel rare qui survient après la vaccination, même chez les personnes qui n’ont jamais contracté la COVID-19.

Abstract 8 | PDF Downloads 3 XML Downloads 7 HTML Downloads 3

References

1. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J. COVID-19-related multisystem inflammatory syndrome in children—United States, March–July 2020. Morb Mortal Wkly Rep. 2020;69(32):1074–1080. https://doi.org/10.1542/gr.44-3-30
2. Amir H, Chagla Z, Jaeschke R, Prebtani A. Survival guide. 1st edition. McMaster University, Department of Medicine Hamilton, ON, Canada [Internet]. Can J Gen Intern Med. 2021 Jul 7;15(5). Available from: https://www.cjgim.ca/index.php/ csim/article/view/453
3. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March–August 2020. Morb Mortal Wkly Rep. 2020;69(40):1450–1456. https://doi.org/10.15585/mmwr.mm6940e1
4. US Center for Disease Control and Prevention (CDC). Multisystem inflammatory syndrome in adults (MIS-A). Case definition information for healthcare providers. CDC 24/7 [Internet]. [cited 2021]. Available from: https://www.cdc.gov/ mis/mis-a/hcp.html.
5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. https://doi.org/10.1056/nejmoa2034577
6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. https://doi.org/10.1056/NEJMoa2035389
7. Salzman MB, Huang C, O’Brien CM, Castillo RD. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination. Emerg Infect Dis. 2021;27(7):1944–1948. https://doi.org/10.3201/eid2707.210594
8. Choi YK, Moon JY, Kim J, et al. Postvaccination multisystem inflammatory syndrome in adult with no evidence of prior SARS-CoV-2 infection. Emerg Infect Dis J. 2022;28(2):411– 414. https://doi.org/10.3201/eid2802.211938
9. Nune A, Iyengar KP, Goddard C, Ahmed AE. Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). BMJ Case Rep. 2021;14(7):1–4. https://doi.org/10.1136/bcr-2021-243888
10. Vogel TP, Top KA, Karatzios C, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3037–3049. https://doi.org/10.1016/j.vaccine.2021.01.054
11. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS– CoV-2 and hyperinflammation in pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72(11):1791–1805. https://doi.org/10.1002/art.41454
12. D’Acquisto F, Crompton T. CD3+CD4-CD8- (double negative) T cells: Saviours or villains of the immune response? Biochem Pharmacol. 2011;82(4):333–340. https://doi.org/10.1016/j.bcp.2011.05.019
13. Brandt D, Hedrich CM. TCRαβ+CD3+CD4−CD8−(double negative) T cells in autoimmunity. Autoimmun Rev. 2018;17(4):422– 430. https://doi.org/10.1016/j.autrev.2018.02.001